-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luveltamab Tazevibulin in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luveltamab Tazevibulin in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luveltamab Tazevibulin in Refractory Acute Myeloid Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luveltamab Tazevibulin in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luveltamab Tazevibulin in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luveltamab Tazevibulin in Epithelial Ovarian Cancer Drug Details: STRO-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Melanoma Drug Details: Ampligen is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Prostate Cancer Drug Details: Ampligen is under development for...
-
Sector Analysis
NewUrea Capacity and Capital Expenditure Outlook by Region, Countries, Companies, Projects and Forecast to 2030
Urea Industry Capacity & Capital Expenditure (Capex) Overview The urea capacity was 241.92 million tonnes per annum (mtpa) in 2023. The use of urea as fertilizer in the agriculture industry and for industrial applications such as for production of plastics is driving global urea demand. Furthermore, Asia, FSU, and the Middle East will primarily drive the global Urea capacity growth during the outlook period. Urea Industry Capacity and Capex Outlook, 2024-2030 (mtpa) Buy the Full Report for More Insights into...
-
Product Insights
Likelihood of Approval Analysis for Cystic Fibrosis
Overview How likely is it that the drugs in Cystic Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cystic Fibrosis Overview Cystic fibrosis (CF) is an inherited disease that causes...
-
Product Insights
Cf & I Pit Mine
The Cf & I Pit Mine is a iron ore mine in United States. It is currently in operation. Empower your strategies with our Cf & I Pit Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability...
-
Thematic Analysis
NewSocial Media in Sport – Thematic Intelligence
An analysis of social media in sport which provides a detailed, yet easy to follow overview of a very important topic in the sport industry. The report will take a look at the key leaders in the industry and a detailed analysis of the social media in sport value chain. Social media’s ad-funded business model is under threat Social media companies will increasingly diversify away from their ad-funded business model in the face of increased regulatory scrutiny. In 2023 alone,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RCT-2100 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RCT-2100 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RCT-2100 in Cystic Fibrosis Drug Details: RCT-2100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APPA-02 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APPA-02 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APPA-02 in Cystic Fibrosis Drug Details: APPA-02 is under development for the...